Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

SHANGHAI and SUZHOU, China, March 21, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2). This...

from PR Newswire: https://ift.tt/3vItkiN